Anika Therapeutics (ANIK) filed an 8-K on November 5, 2025, reporting Q3 2025 financial results and significant regulatory updates.
Q3 2025 Financial Performance: Revenue totaled \(27.8 Million, marking a 6% year-over-year decline. This was driven by a +22% increase in Commercial Channel revenue (led by Integrity System outperformance) offsetting a -20% expected decline in OEM Channel revenue due to lower U.S. partner pricing. Adjusted EBITDA from continuing operations was \)0.9 Million. Management noted improved efficiency, with operating expenses decreasing 3% and SG&A down 12%.
**Guidan
...